Stealth

Seegene Rapidly Introduces New PCR Test that Identifies the Omicron Variant, its Stealth Version, and all VOCs in a single tube

Retrieved on: 
Thursday, December 9, 2021
PCR, RT, COVID-19, Technology, Stealth, World Health Organization, RNA-dependent RNA polymerase, Multimedia, World, N501Y, Alpha-beta model, KQ, Severe acute respiratory syndrome coronavirus 2, WHO, Medical device, Vaccine

The Novaplex SARS-CoV-2 Variants VII assay addresses Omicron and its stealth version, as well as other variants.

Key Points: 
  • The Novaplex SARS-CoV-2 Variants VII assay addresses Omicron and its stealth version, as well as other variants.
  • Seegene believes the new PCR test will be effective in helping governments and health authorities to fight current variants.
  • Immediately after the World Health Organization (WHO) announced a discovery of the Omicron variant, Seegene implemented its AI-based in-silico system to conclude this development within a week.
  • Today, Seegene is able to rapidly develop new tests ahead of emerging variants using the company's big data auto-surveillance in silico system.

Seegene Rapidly Introduces New PCR Test that Identifies the Omicron Variant, its Stealth Version, and all VOCs in a single tube

Retrieved on: 
Thursday, December 9, 2021
PCR, RT, COVID-19, Technology, Stealth, World Health Organization, Alpha, RNA-dependent RNA polymerase, World, N501Y, Alpha-beta model, KQ, Severe acute respiratory syndrome coronavirus 2, WHO, Medical device, Vaccine

SEOUL, South Korea, Dec. 9, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today unveiled another series of diagnostic test that detects the ever-changing COVID-19 variant landscape. The Novaplex™ SARS-CoV-2 Variants VII assay addresses Omicron and its stealth version, as well as other variants. Seegene believes the new PCR test will be effective in helping governments and health authorities to fight current variants.

Key Points: 
  • The new assay identifies positive COVID-19 cases and distinguishes between Alpha, Beta, Gamma, Delta, Omicron and its Stealth version.
  • The Novaplex SARS-CoV-2 Variants VII assay addresses Omicron and its stealth version, as well as other variants.
  • Seegene believes the new PCR test will be effective in helping governments and health authorities to fight current variants.
  • Immediately after the World Health Organization (WHO) announced a discovery of the Omicron variant, Seegene implemented its AI-based in-silico system to conclude this development within a week.

VIZIO Expands its Popular WatchFree+ Streaming Service with Access to Hundreds of Free Channels -- Now with Thousands of Free On Demand Titles

Retrieved on: 
Wednesday, December 1, 2021
Internet, Audio, Video, Film & Motion Pictures, Hardware, Online, Consumer Electronics, Technology, Entertainment, Lazarus, AVOD, Interview, News, Sport, The Boondock Saints, LOL, Lion, Time, Air Force One, Music, NYSE, Tears, Athlete, Crime, Lazarus effect, Founder, Shopaholic, Atmosphere of Earth, Sony Pictures, Vizio, Season, Sun, Catalog, Multimedia, Confessions, Stealth, Disney Media and Entertainment Distribution, Video game, Film, Television

VIZIO Expands its Popular WatchFree+ Streaming Service with Access to Hundreds of Free Channels -- Now with Thousands of Free On Demand Titles (Graphic: Business Wire)

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211201005392/en/
    VIZIO Expands its Popular WatchFree+ Streaming Service with Access to Hundreds of Free Channels -- Now with Thousands of Free On Demand Titles (Graphic: Business Wire)
    With this addition, SmartCast users can now access hundreds of existing WatchFree+ live streaming channels, as well as thousands of on demand titles, with no subscriptions, logins, or devices required for unlimited viewing.
  • WatchFree+ will deliver more than 4,000 free movies, TV shows, and VIZIO exclusives to SmartCast audiences on demand from more than 17 content and studio partners.
  • With over 5,000 hours of on demand programming across genres including action, romance, comedy, family entertainment, crime, and more, theres truly something for everyone.
  • VIZIO recently launched the reimagined WatchFree+ free streaming service in August 2021, offering an ever-expanding library with hundreds of free channels spanning movies, news, sports, music, kids/family, and more.

Ore System Announces Its Next Gen NFTs

Retrieved on: 
Tuesday, November 9, 2021
Android, IOS, Protocol, Stealth, Decentralized finance, Next, ORE, Box, Linux, NFT, Mac, PC, Non-fungible token, Forge, Video game, Cryptocurrency

It is proud to announce its next gen NTFs that the Next Gen gamers can leverage to improve their gaming activities.

Key Points: 
  • It is proud to announce its next gen NTFs that the Next Gen gamers can leverage to improve their gaming activities.
  • The Ore System team defines it as "a next-generation blockchain technology that creates value for content creators, collectors, and studios with three major components: the Ore token, the Ore forge, and the Ore SKD."
  • The Ore System is designed to meet the growing need for a platform for developers to directly enable NFT integration into their system.
  • Hence, the system will help with integrating NFTs into games development for next-generation and large-scale gaming.

Stealth BioTherapeutics to Report Third Quarter Financial Results on Thursday, November 11

Retrieved on: 
Thursday, November 4, 2021
Degenerative disease, Friedreich's ataxia, Investor, Elamipretide, Eye, Brain, Webcast, Stealth, Lists of diseases, Nasdaq, Leber's hereditary optic neuropathy, Duchenne muscular dystrophy, Heart, IgG4-related ophthalmic disease, DNA, Pharmaceutical industry

BOSTON, Nov. 4, 2021 /PRNewswire/ --Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announcedthat it will report third quarter 2021 financial results on Thursday, November 11, before the market opens.

Key Points: 
  • BOSTON, Nov. 4, 2021 /PRNewswire/ --Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announcedthat it will report third quarter 2021 financial results on Thursday, November 11, before the market opens.
  • Management will host a conference call at8:30 am ETthat day to discuss the financial results and provide a general business update.
  • The call can be accessed by dialing (877)-407-0989 (domestic) or(201)-389-0921 (international) and referencing conference ID 13723309.
  • A live audio webcast of the event can be accessed by visiting the Investors & News section of Stealth's Investor website, https://investor.stealthbt.com/ .

FDH Aero Acquires Stealth Aerospace

Retrieved on: 
Monday, October 18, 2021
Professional Services, Defense, Aerospace, Manufacturing, Finance, Other Defense, MRO, History, Private equity, AOG, Consumer, FDH, Stealth, CEO, Family, Audax, Partnership, CA, Acquisition, Weapon, Financial services

FDH Aero (FDH), an aerospace and defense products distributor serving aircraft production and aftermarket supply chains, has acquired Stealth Aerospace (Stealth).

Key Points: 
  • FDH Aero (FDH), an aerospace and defense products distributor serving aircraft production and aftermarket supply chains, has acquired Stealth Aerospace (Stealth).
  • Stealth Aerospace, founded in 1995, is a stocking distributor of aerospace electrical and electro-mechanical components including relays, switches, connectors, lamps, avionic components, latches, wire & cable and other electrical products to the airlines and aerospace industry worldwide.
  • Based in Southern California, Stealth brings to FDH a leader in the U.S. commercial and cargo aerospace aftermarket, strengthening FDHs ability to serve its global aftermarket customer base.
  • Stealths partnership with FDH will enhance our ability to provide best-in-class support to our customers, said Alon Glickstein, President of Stealth Aerospace.

Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting

Retrieved on: 
Thursday, October 7, 2021
Forward-looking statement, Lists of diseases, Brain, FTLD, Stealth, PSP, Amyotrophic lateral sclerosis, Degenerative disease, Leber's hereditary optic neuropathy, Neurodegeneration, Friedreich's ataxia, Traffic barrier, COVID-19, Heart, Marketing, Duchenne muscular dystrophy, Neuron, Safety, Annual report, ALS, Alzheimer's disease, U.S. Securities and Exchange Commission, IgG4-related ophthalmic disease, Frontotemporal lobar degeneration, Private Securities Litigation Reform Act, LBD, Pathology, Neurite, Hope, Elamipretide, TAR, Mitochondrial disease, Barth syndrome, DNA, Eye, Patient, Risk, Nasdaq, Parkinson's disease, Pharmaceutical industry

The data were presented at the virtual 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting held October 6-7, 2021.

Key Points: 
  • The data were presented at the virtual 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting held October 6-7, 2021.
  • This preclinical study evaluated the effects of SBT-272 on mitochondrial function, morphology, and motility in mouse corticospinal motor neurons with mutant TDP-43 pathology.
  • We are evaluating our second-generation clinical-stage candidate, SBT-272, and our new series of small molecules, SBT-550, for rare neurological disease indications following promising preclinical data.
  • Such forward-looking statements include, but are not limited to, those regardingthe implications of preliminary preclinical data.

Cardiovascular Systems, Inc. Announces First Patient Treated with ViperCross™ Peripheral Support Catheter

Retrieved on: 
Wednesday, September 29, 2021
Medical Devices, Health, Surgery, Research, Cardiology, Science, Diamondback, News, Leg, Moyamoya disease, Annual report, Walking, Risk, Calcium, Coronary artery disease, Plaque, Sale, Private Securities Litigation Reform Act, NASDAQ, Testosterone and the cardiovascular system, FDA, USA, Patient, Catheter, CSI, Atherectomy, Physician, PVI, MD, Stent, Hospital, Heart, Form 10-K, PAD, Diabetes, Twitter, Pain, Prevalence, Contraindication, Anatomy, Peripheral artery disease, Obesity, Fracture, Â, Stealth, Organization, Amputation, SEC, Form 10-Q, Pharmaceutical industry, Medical device, Medical imaging, Cardiovascular Systems, Inc., Peripheral Artery Disease (PAD), CARDIOVASCULAR SYSTEMS, INC., PERIPHERAL ARTERY DISEASE (PAD)

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient has been successfully treated with its ViperCross peripheral support catheter.

Key Points: 
  • Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient has been successfully treated with its ViperCross peripheral support catheter.
  • Dr. Billy J. Kim, MD, The Surgical Clinic, Nashville, Tenn., treated the first patient with ViperCross.
  • Peripheral support catheters are used during peripheral vascular intervention (PVI) procedures for guidewire support to enable lesion crossing, as well as for guidewire exchanges.
  • The 014 ViperCross support catheters are intended to be used to access discrete regions of the peripheral and/or coronary vasculature.

Stealth Power Launches Electric Power Take-Off (ePTO) Solution Expanding the Company's Offerings for Utilities Sector

Retrieved on: 
Monday, September 27, 2021
Efficiency, USA, Multimedia, FAA, CEO, FDNY, Utility, Intelligence, U.S. Customs and Border Protection, Maintenance, Stealth, Weapon

AUSTIN, Texas, Sept. 27, 2021 /PRNewswire/ -- Stealth Power , the idle mitigation and mobile power company, today announces the launch of its Stealth Electric Power Take-Off (ePTO) System.

Key Points: 
  • AUSTIN, Texas, Sept. 27, 2021 /PRNewswire/ -- Stealth Power , the idle mitigation and mobile power company, today announces the launch of its Stealth Electric Power Take-Off (ePTO) System.
  • By combining ePTO, together with idle mitigation capabilities, Stealth is able to offer the most compelling ePTO solution on the market.
  • "Stealth's ePTO replaces the need to run an engine to drive existing inefficient hydraulic power take-off systems," said Devin Scott, CEO, Stealth Power.
  • Stealth Power designs and builds idle mitigation and scalable mobile power systems that power complex fleet operations into the future.

Stealth BioTherapeutics to Showcase Leadership in Retinal Mitochondrial Health with Clinical Updates at Ophthalmic Conferences

Retrieved on: 
Tuesday, September 14, 2021
Friedreich's ataxia, American Academy of Ophthalmology, Barth syndrome, Pathology, Drusen, 2021 Essex County Council election, Patient, Heart, American Academy, OCT, Safety, Efficacy, Stealth, Health, Geography, Society, Natural history, Lists of diseases, Degenerative disease, Disease, ASRS, AAO, Association, IgG4-related ophthalmic disease, Pharmacokinetics, DNA, Leber's hereditary optic neuropathy, Duchenne muscular dystrophy, Brain, Elamipretide, Eye, GA, AMD, Geographic atrophy, Pharmaceutical industry, Animal, Environmental remediation, Medical imaging

"GA is a progressively blinding disease which contributes to a loss of independence for affected individuals," said Chief Executive Officer Reenie McCarthy.

Key Points: 
  • "GA is a progressively blinding disease which contributes to a loss of independence for affected individuals," said Chief Executive Officer Reenie McCarthy.
  • Secondary functional endpoints are change in low-luminance reading acuity and best-corrected visual acuity (BCVA), as well as patient-reported assessments of visual quality of life.
  • The data showed improvements from baseline in LLVA and BCVA for patients with GA and drusen who completed the trial.
  • We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction.